A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPD
Study objective: Inhaled bronchodilators are the first-line pharmacotherapy against COPD. The purpose of the present study was to investigate the effects of β 2 -agonists and anticholinergic agents on the exercise capacity of patients with COPD. Methods: A total of 67 stable patients with COPD were...
Saved in:
Published in | Chest Vol. 123; no. 6; pp. 1810 - 1816 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Northbrook, IL
American College of Chest Physicians
01.06.2003
Elsevier B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Study objective: Inhaled bronchodilators are the first-line pharmacotherapy against COPD. The purpose of the present study was to investigate
the effects of β 2 -agonists and anticholinergic agents on the exercise capacity of patients with COPD.
Methods: A total of 67 stable patients with COPD were recruited at the Kyoto University Hospital. After inhaling 400 μg salbutamol,
80 μg ipratropium bromide, or an identical placebo in a randomized, double-blind, crossover fashion, the patients performed
cycle endurance tests at a constant workload of 80% of the maximum work rate reached on progressive cycle ergometry, and the
endurance time was recorded.
Results: Both salbutamol and ipratropium bromide significantly improved the endurance time by 29 s (15%; p < 0.001) and 27 s (14%;
p < 0.001), respectively, in comparison with the placebo. However, there was no statistically significant difference between
them (p = 0.71). The dyspnea ratios were also similarly reduced by both bronchodilators. The difference in the endurance time
between therapy with salbutamol and placebo was significantly, but moderately, related to the difference between therapy with
ipratropium bromide and placebo. In addition, there were no relationships, or only weakly significant relationships, between
the change in FEV 1 and the change in the endurance time, the highest oxygen uptake, and the highest minute ventilation for both salbutamol and
ipratropium bromide.
Conclusions: Therapy with both salbutamol and ipratropium bromide improved exercise capacity, as evaluated by the endurance time, and
reduced dyspnea similarly in patients with COPD. In addition, the effects of the different bronchodilators on exercise capacity
varied within individuals, and a complex mechanism may be responsible for the different effects of these two bronchodilators
on exercise capacity vs airflow limitation. These results support the conclusion that both types of inhaled bronchodilators
can be used as first-line drugs for the treatment of stable patients with COPD. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
ISSN: | 0012-3692 1931-3543 |
DOI: | 10.1378/chest.123.6.1810 |